“The FDA has begun targeting illicit peptide sellers,” says health expert Sally Pipes. “Now it needs to address the supply chains that keep them in business.”
Getty Images
The online market for unapproved injectable peptides is booming. Sellers promise everything from weight loss and muscle growth to faster recovery. Federal regulators are starting to crack down. But the sprawling international supply chain behind these products makes enforcement complicated.
In August, the Food and Drug Administration sent warning letters to several companies marketing unapproved peptides online. Among the substances identified was retatrutide, an experimental weight-loss drug still undergoing clinical trials.
Those letters represent an important step toward holding companies accountable for illicit behavior. But behind the websites selling these products is a network of overseas manufacturers and distributors that can be difficult for U.S. authorities to penetrate.
Peptides themselves are nothing new. They’re short chains of amino acids that perform important functions throughout the body. Many are valuable medicines. Insulin is a peptide, as are blockbuster GLP-1 drugs such as Wegovy and Ozempic.
Unlike FDA-approved peptide medicines, many compounds marketed online have never undergone rigorous clinical testing or regulatory review. That leaves fundamental questions about their safety and effectiveness unanswered.
The bigger challenge is the supply chain. Overseas manufacturers can profit from American demand while making it difficult for U.S. authorities to enforce the laws governing drug imports.
China is a major source of these products. According to an analysis of import records conducted by the Partnership for Safe Medicines, at least eight shipments of retatrutide entered the U.S. supply chain from Chinese manufacturers during the first quarter of 2026. Some contained several kilograms of the ingredient. As the Partnership noted, bulk imports of an experimental drug by third-party suppliers raise significant patient-safety concerns.
The money flowing through this market is substantial. Blockchain analytics firm Chainalysis estimates that cryptocurrency transactions involving gray-market peptide vendors reached $32 million in the first quarter of 2026, up 159% from the previous quarter. That put the market on pace to exceed $100 million annually in cryptocurrency transactions alone.
Some suppliers have troubling histories. According to the Wall Street Journal, blockchain analytics firm TRM Labs has identified at least 50 companies selling peptides among more than 200 businesses it had tracked for selling fentanyl precursors. Some of those companies have been indicted in the United States for their alleged roles in the fentanyl trade.
Suppliers have also developed ways to make their products harder to track. Additional reporting from the Wall Street Journal found that Chinese shippers have concealed individual peptide orders inside larger packages falsely labeled as ordinary merchandise, such as snacks. Customs officers in Cincinnati have disrupted roughly 400 such smuggling attempts containing nearly 6,000 individual peptide orders.
Even the FDA’s import safeguards can be circumvented. In September, the attorneys general of 20 states highlighted the case of Harbin Jixianglong Biotech, a Chinese manufacturer on an FDA list whose members’ GLP-1 ingredients were not subject to automatic detention at the border. According to an FDA warning letter, Harbin obtained semaglutide ingredients from a facility outside that list, relabeled them as its own, and then shipped them to the United States.
FDA inspectors uncovered the violations, and the agency removed Harbin from the list in February. The case illustrates how difficult it can be to verify the origins of imported pharmaceutical ingredients.
Federal authorities need to focus more attention on the origins of these products. That means closer coordination between the FDA and Customs and Border Protection, greater scrutiny of suppliers that misrepresent where their ingredients were manufactured, and tougher enforcement against companies that knowingly circumvent import restrictions.
None of this requires obstructing legitimate pharmaceutical manufacturing or peptide research. It requires making the companies supplying the American market accountable for complying with U.S. drug laws.
The FDA has begun targeting illicit peptide sellers. Now it needs to address the supply chains that keep them in business.
Leave a comment